Skip to content

Clinical Study on Xianglian Huazhuo Granules to Block ''Inflammation-Carcinoma Transformation'' of Chronic Atrophic Gastritis

Clinical Study on Xianglian Huazhuo Granules to Block ''Inflammation-Carcinoma Transformation'' of Chronic Atrophic Gastritis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005208
Enrollment
Unknown
Registered
2021-09-11
Start date
2021-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic gastritis

Interventions

control group:placebo
Chinese Medicine Group:Xianglian Huazhuo Recipe for oral administration without decoction

Sponsors

Hebei Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meet the above-mentioned diagnostic criteria of Chinese and Western medicine; (2) Atrophic gastritis was diagnosed by electronic gastroscopy and histopathology in our hospital before enrollment; (3) Aged between 18 and 65 years old, no gender limit; (4) Subjects are informed and voluntarily sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Autoimmune gastritis (type A chronic atrophic gastritis); (2) Patients with gastric and duodenal ulcers, upper gastrointestinal bleeding; (3) Patients with severe dysplasia of gastric mucosa and suspected malignant transformation in mucosal pathology diagnosis; (4) Patients with serious organic diseases, such as heart (heart function NYH?-?, myocardial infarction, severe arrhythmia, etc.), brain, liver, kidney, lung and blood system and other serious primary diseases; (5) Those who have a history of allergies to the known drugs or ingredients in the study; (6) Unable to cooperate with the study if combined with severe mental illness; (7) Pregnant or lactating women; (8) Patients who are participating in other drug clinical trials or stopping the last drug research for less than one month; (9) Those who cannot cooperate with follow-up and investigation; (10) Other circumstances deemed inappropriate by the researcher.

Design outcomes

Primary

MeasureTime frame
Histopathology;

Countries

China

Contacts

Public ContactQian Yang

Hebei Provincial Hospital of Traditional Chinese Medicine

361903581@qq.com+86 13832355120

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026